Loading clinical trials...
Loading clinical trials...
Randomized, Parallel Arm, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Healthy Subjects
Conditions
Interventions
Phentolamine Ophthalmic Solution 0.75%
Phentolamine Ophthalmic Solution Vehicle (Placebo)
Locations
12
United States
Clinical Site 11
Newport Beach, California, United States
Clinical Site 10
San Diego, California, United States
Clinical Site 9
Longwood, Florida, United States
Clinical Site 6
Orlando, Florida, United States
Clinical Site 2
Roswell, Georgia, United States
Clinical Site 7
Pittsburg, Kansas, United States
Start Date
November 18, 2020
Primary Completion Date
December 23, 2020
Completion Date
March 15, 2021
Last Updated
September 11, 2023
NCT06290713
NCT06675825
NCT04372563
NCT05424263
NCT06454084
NCT07364188
Lead Sponsor
Ocuphire Pharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions